Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended April 1, 2001, for PerkinElmer, Inc. (Note: The metadata lists "REVVITY, INC.", but the filing text identifies the registrant as PerkinElmer, Inc., which later became Revvity). The company operates in four segments: Life Sciences, Optoelectronics, Instruments, and Fluid Sciences. It is a component of the S&P 500 Index with operations in over 100 countries.
Key Financial Metrics
| Metric | Q1 2001 | Q1 2000 |
|---|---|---|
| Sales (Revenue) | $425.7 million | $402.3 million |
| Net Income | $23.5 million | $16.2 million |
| Diluted EPS | $0.45 | $0.32 |
| Operating Income | $51.2 million | $35.9 million |
| Cash Flow from Operations | $9.8 million | $12.3 million |
| Cash and Equivalents | $136.7 million | $125.6 million (Dec 31, 2000) |
| Total Debt (Short + Long Term) | $814.0 million | $769.5 million (Dec 31, 2000) |
| Short-Term Debt | $228.3 million | $186.2 million |
| Long-Term Debt | $585.7 million | $583.3 million |
Margins: Operating margin was approximately 12.0% in Q1 2001 compared to 8.9% in Q1 2000. Net income margin was 5.5% in Q1 2001 versus 4.0% in Q1 2000.
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 6% ($23.4 million) driven by 5% organic growth and the inclusion of the NEN Life Sciences acquisition.
- Profitability: Net income increased 45% year-over-year. Operating income rose 43%.
- Restructuring: The company recorded a $1.5 million credit (reversal) for restructuring costs in Q1 2001 due to lower-than-anticipated employee separation costs, compared to a $2.4 million charge in Q1 2000.
- Acquisition Charges: In-process R&D charges were $2.5 million in Q1 2001, significantly lower than the $8.1 million charged in Q1 2000.
- Dispositions: Gains on dispositions were $3.9 million in Q1 2001, down from $7.8 million in Q1 2000.
- Interest Expense: Other expense increased to $13.7 million from $8.6 million, primarily due to higher interest costs on debt incurred for acquisitions.
Guidance, Outlook, and Risks
- Segment Performance:
- Life Sciences: Revenues surged 75% due to the NEN acquisition; operating profit before nonrecurring items increased 119%.
- Optoelectronics: Revenues grew 6% driven by telecom and digital imaging; operating profit before nonrecurring items rose 29%.
- Instruments: Revenues declined 11% due to the sale of the Berthold business and softness in aviation security markets.
- Fluid Sciences: Revenues increased 13%; operating profit before nonrecurring items rose 47%.
- Restructuring Outlook: The company expects to incur at least $20 to $25 million in cash outlays for restructuring plans throughout fiscal 2001.
- Stock Split: A two-for-one stock split was approved and is effective June 1, 2001. Pro forma EPS for Q1 2001 would be $0.23.
- Risks: The company faces market risks related to interest rates and foreign exchange fluctuations. It utilizes derivative instruments to hedge these exposures but notes that forecast errors could lead to unanticipated gains or losses.
Investor Verification Checklist
- Verify the impact of the NEN Life Sciences acquisition on future organic growth rates, as Q1 2001 revenue growth was heavily influenced by this purchase.
- Monitor the $20-$25 million expected cash outlay for restructuring in fiscal 2001 and its effect on liquidity.
- Review the convertible debentures ($471 million) maturing in 2020, noting the total repayment obligation of $921 million at maturity.
- Assess the sustainability of the Fluid Sciences segment's profit improvement following the sale of unprofitable businesses.
- Confirm the pro forma adjustments for the two-for-one stock split when comparing future EPS figures.